Literature DB >> 3458696

Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.

S Lauwers, W Vincken, A Naessens, D Pierard.   

Abstract

Sixteen patients, 14 with an infection of the lower respiratory tract and two with cholangitis, were treated with pefloxacin 400 mg bid or tid. The original pathogens were eradicated in all but one patient. Pefloxacin therapy resulted in clinical cure in 11 patients, three patients were improved clinically and in two patients a clinical failure was observed. No adverse effects were noticed during or after pefloxacin administration.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3458696     DOI： 10.1093/jac/17.suppl_b.111

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

1.  Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections.

Authors:  H Giamarellou; G Perdikaris; N Galanakis; G Davoulos; K Mandragos; P Sfikakis
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit.

Authors:  D M Boland; W C van Gestel; D M MacLaren; D de Jong
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

Review 3.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 5.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 6.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

7.  Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

Authors:  K V Rolston; D H Ho; B LeBlanc; G Gooch; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

8.  Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment.

Authors:  P Jungers; D Ganeval; T Hannedouche; B Prieur; G Montay
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Pharmacokinetics and tissue penetration of orally administered pefloxacin.

Authors:  J M Webberley; J M Andrews; J P Ashby; A McLeod; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.